本研究系统探讨了鸡肉肽-亚铁螯合物（CMP-Fe）对缺铁性贫血（IDA）小鼠贫血症状的改善作用，并从体重变化、血常规参数、铁代谢指标、炎症反应及组织病理学等多个方面综合评价其干预效应。实验结果表明：与模型组相比，CMP-Fe各剂量组（（小剂量组：1.0 mg Fe/kg·bw；中剂量组：2.0 mg Fe/kg·bw；高剂量组：3.0 mg Fe/kg·bw.））小鼠的体重、血常规指标（包括RBC（红细胞计数）、HGB（血红蛋白）、HCT(红细胞压积) 、MCV（平均红细胞体积）、MCH（平均红细胞血红蛋白含量）、MCHC（平均红细胞血红蛋白浓度）、RDW-CV（红细胞分布宽度-变异系数））及血清铁代谢指标（SI (血清铁)、TIBC (总铁结合力)、TFR（转铁蛋白受体)、FER (铁蛋白) 、TSAT (转铁蛋白饱和度) 和UIBC（不饱和铁结合力））均出现显著改善，且高剂量组效果最为显著。。其中，高剂量 CMP-Fe 的干预效果尤为突出。CMP-Fe对红细胞系指标（RBC、HGB、HCT等）的改善作用与阳性对照组相当，并呈现明显的剂量（小、中、高）依赖性。在炎症调控方面，CMP-Fe可抑制血清及结肠促炎因子（IL-6、TNF-α和 CRP）的产生，并提升抑炎因子IL-10及肠道黏膜免疫标志物sIgA的水平。具体而言，CMP-Fe组小鼠结肠组织中促炎因子IL-6、TNF-α及CRP水平均较模型对照组显著降低（P<0.05），从而调节IDA小鼠的炎症反应。表明其能够有效调节IDA伴随的炎症反应。尤其在高剂量CMP-Fe干预下，sIgA水平恢复效果优于模型组（P < 0.05），并甚至超过阳性对照组。组织病理学检查显示，CMP-Fe对小鼠的心、肺、脾、肾等器官未见病理性损伤，说明其具有良好的生物安全性。同时，其还可显著缓解因铁缺乏引起的肠道及肝脏组织病理损伤。综上所述，CMP-Fe能够有效改善IDA小鼠的铁代谢紊乱、抑制炎症反应，并减轻肠道和肝脏的组织损伤，具备良好的安全性，是一种具有开发潜力的新型有机补铁剂，可用于猫、狗等多种宠物专用粮及营养补充剂的产品开发。

This study systematically investigated the ameliorative effect of chicken breast peptide-iron chelate (CMP-Fe) on anemia symptoms in mice with iron-deficiency anemia (IDA), focusing on body weight, blood routine parameters, iron metabolism, inflammation, and tissue protection. Compared with the model group, all CMP-Fe dose groups(Low Dose：1.0 mg Fe/kg·bw；Middle Dose：2.0 mg Fe/kg·bw；High Dose：3.0 mg Fe/kg·bw) exhibited significant improvements in body weight, blood routine indicators [red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width-coefficient of variation (RDW-CV)] and serum iron metabolism markers [serum iron (SI), total iron-binding capacity (TIBC), transferrin receptor (TFR), ferritin (FER), transferrin saturation (TSAT), unsaturated iron-binding capacity (UIBC)]. Notably, the high-dose CMP-Fe exerted a particularly prominent intervention effect: in terms of body weight improvement, its efficacy even exceeded that of the blank control group; while its amelioration of red blood cell indices was comparable to that of the positive control group. Furthermore, CMP-Fe significantly inhibited the production of pro-inflammatory factors (IL-6, TNF-α, and CRP) in serum and colon, and increased the anti-inflammatory factor (IL-10) and intestinal sIgA of IDA mice. Moreover, the regulatory effect of high-dose CMP-Fe on sIgA levels in IDA mice was superior to positive group. Meanwhile, CMP-Fe caused no pathological damage to the heart, lungs, spleen, kidneys of mice, and could alleviate pathological injuries in intestinal and liver tissues induced by a low-iron diet.  In conclusion, CMP-Fe effectively alleviates IDA symptoms in mice with high safety, making it a promising organic iron supplement. It can be developed as a specialized iron additive for cat food and other pet-related products.